At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 110,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care, and Agricultural Solutions.
Lead Pharma discovers, develops, and commercializes innovative therapeutics against cancer and autoimmune diseases. The company has unparalleled expertise in the discovery and optimization of first- and best-in-class small molecules for challenging drug targets. Lead pharma’s drug discovery engine combines adept medicinal, structural, and computational chemistry capability with complementary expertise in the fields of cell biology and omics technologies. The company’s innovative approach enables isolation, purification, and manufacture of target proteins and the development of biochemical, cellular, and functional reporter assays as well as biomarkers.
We are Merck, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.
Using a predictive computational platform to discover untapped drug targets and extend the reach of cancer immunotherapies to new patient populations
Domainex is a leading integrated drug discovery CRO and has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organizations around the world.
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive. Our ambition is to accelerate progress and see 3 in 4 patients surviving the disease by 2034.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.
AstraZeneca is committed to discovering and developing compounds that improve patient care in neuroscience. With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders.
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.
As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority. Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives. As people live longer, chronic conditions are on the rise. New viruses and diseases are emerging, while old enemies like cancer and neurodegenerative diseases remain. Sanofi is driven by the scope of these health challenges.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need. Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development. Antabio intends to work with partners to fully capitalize on the multiple value creating opportunities offered by its broad and innovative programs. Antabio is led by an international team of experts focused on understanding and resolving the most urgent unmet medical needs in antimicrobial resistance.
Progenra, Inc. pursues novel approaches to exploit the ubiquitin proteasome system for drug discovery in numerous therapeutic areas. Its UbiPro™ Drug Discovery Platform is a multi-faceted approach based on the physiological milieux in which enzymes of the ubiquitin proteasome system interact with their substrates. This approach has led to breakthroughs in developing drug candidates for evaluation and progression in the clinic.
Pharmaxis Limited is an Australian pharmaceutical research company and a global leader in drug development for inflammation and fibrotic diseases. The company has a highly productive drug discovery engine with drug candidates in clinical trials. Leveraging its small‐molecule expertise and proprietary amine oxidase chemistry platform, Pharmaxis has taken four in‐ house compounds to Phase 1 trials in just five years. Pharmaxis is listed on the Australian Securities Exchange (PXS)
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx’s lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies [with top line data expected in H1 2021] and the Company’s selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021. The Company’s core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.
The Sussex Drug Discovery Centre (SDDC) is a fully integrated group of drug discovery scientists, equipped with industry-standard equipment and capabilities, based at the University of Sussex. Our goal is the discovery of novel therapeutics for diseases with high unmet medical need.
The Moulder Center for Drug Discovery Research was dedicated on May 14, 2009 and is currently home to a talented and enthusiastic group of scientists. The team is dedicated to facilitating collaborative research efforts to support the discovery and development of novel therapeutic agents to improve the health and life of patients. The Moulder Center serves as a multidisciplinary research hub for the further development of scientific discoveries identified by Temple University faculty and scientists, enabling their research to move beyond the lab and into the broader research community. In addition, the Moulder Center’s unique capabilities and experienced scientists actively pursue collaborative research opportunities with external collaborators in the academic community and industrial partners both in the U.S. and abroad.
MEDINA is leader in Drug Discovery from Microbial Natural Product Libraries and internal High Throughput Screening (HTS) programs are focused on strategic therapeutic areas: Infectious and Parasitic Diseases, Oncology and Neurodegeneration.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. With more than 7,600 people in approximately 40 countries, the company generated revenue of €4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB).
IRBM is a Contract Research Organization with expertise in advancing integrated drug discovery projects, having delivered 25 preclinical candidates and four drugs that are currently on the market. With all their world-class facilities on one site, fully integrated programs are executed under one roof. IRBM works with pharmaceutical companies, non-profit organizations and academic institutions, to quickly and efficiently advance their projects through the drug discovery and development pipeline.
IMB is a global leader in multidisciplinary life sciences research, bringing together 500 researchers from across the globe for disease discovery, application and sustainable futures. Formed in 2000 as an initiative of The University of Queensland, State and Federal Governments and private philanthropy, IMB is one of the largest life sciences institutes in the Asia-Pacific region. It has capitalised on one of the greatest periods of discovery in history – the genetic and molecular basis of life and its diversity. Our research is framed through six research centres focusing on superbug infection, pain, heart disease, inflammation, solar biotechnology and the interplay of genomics and disease. We also undertake research in cancer, brain injury and disease, the environment and agricultural solutions.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy. Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated as one of the top centres for cancer research and treatment worldwide. As well as being as world-class research institute, the ICR is a higher education institution and a college of the University of London.
Grünenthal is a global leader in the treatment of pain and related diseases. As a family-owned research-based pharmaceutical company, we have many years of experience in innovative pain therapy and the development of cutting-edge technologies for patients worldwide. We want to improve the lives of patients with innovations. We are doing all we can to achieve our vision of a world free of pain. Grünenthal has its corporate headquarters in Aachen and is represented by around 30 companies in Europe, Latin America and the United States. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of 1.3 billion euros.
Euroscreen FAST, a business unit of EPICS Therapeutics SA. As part of the original Euroscreen S.A. spin-off founded in 1994, we’ve benefited from a buoyant research and development environment focused on GPCR science. This expertise was nurtured over the past two decades by taking part in many GPCR deorphanization programs, developing hundreds of assays, and assisting our customers in their drug discovery efforts.
The Cancer Research UK Cancer Therapeutics Unit is the largest academic cancer drug discovery and development group worldwide. Its research teams cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials. The mission of the CRUK Cancer Therapeutics Unit is: To discover and develop effective therapeutics for the treatment of cancer Exploit the addictions, dependencies and vulnerabilities of cancer cells to develop innovative small molecule drugs Prioritise novelty and unmet clinical need in defined patient populations
As one of Cancer Research UK’s core-funded institutes, we have built an excellent reputation for basic cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis. Our goal for the future is for this discovery work to continue apace but for it to also be applied to preclinical and clinical studies. In particular, our research places an emphasis on the following key themes: Cancer vulnerabilities caused by energetic stress and aberrant metabolism; Interplay between the tumour microenvironment, metastasis and recurrence; and Biology of early disease, aimed at developing a ‘precision prevention’ approach.
CHDI Foundation, Inc. is a privately-funded nonprofit biomedical research organization that is exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease. As a collaborative enabler CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 700 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus.
Cancer Therapeutics CRC is an oncology focused small molecule drug discovery and early development biotechnology group, established under the Australian government’s Cooperative Research Centre Program. Cancer Therapeutics CRC’s unique partnership model leverages the capabilities and expertise of its Industry Participants with several of Australia’s pre-eminent Medical Research Institutes and Universities. The CRC Participants are the Children’s Cancer Institute, CSIRO, Griffith University, Melbourne Health, Monash University, National Cancer Centre Singapore, Peter MacCallum Cancer Centre, Walter & Eliza Hall Institute of Medical Research, Clinical Genomics, SYNthesis Research, CTxONE, Cancer Trials Australia, Medicines Development for Global Health Limited, Cancer Council of Victoria, Syneos Health and the Victorian Comprehensive Cancer Centre.
We fund scientists, doctors and nurses to help beat cancer sooner. We also provide cancer information to the public.
C4X Discovery (C4XD) aims to create the world’s most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company’s business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m. C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD’s commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.